Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037435 | 0.82 | CHRM2 (0.45) | OGACYP2D6 | |
| SCHEMBL23132887 | 0.80 | P2RX7 (0.45) | LTA4HOGALRRK2ALDH1A1CYP3A4 | |
| SCHEMBL23089232 | 0.79 | DEGS1 (0.47) | LRRK2ALDH1A1TSHR | |
| SCHEMBL23090514 | 0.79 | LTA4H (0.41) | LTA4HTLR8TLR7OGALRRK2 | |
| SCHEMBL29814584 | 0.79 | PIK3CA (0.43) | LTA4HOGAPIK3CACYP3A4TSHR | |
| SCHEMBL29814647 | 0.79 | LTA4H (0.41) | LTA4HTLR8TLR7OGALRRK2 | |
| SCHEMBL23103438 | 0.79 | LTA4H (0.41) | LTA4HTLR8TLR7OGALRRK2 | |
| SCHEMBL23103435 | 0.79 | LTA4H (0.41) | LTA4HTLR8TLR7OGALRRK2 | |
| SCHEMBL113875 | 0.79 | LTA4H (0.41) | LTA4HOGALRRK2PIK3CAALDH1A1 | |
| SCHEMBL23103433 | 0.79 | LTA4H (0.41) | LTA4HTLR8TLR7OGALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | LTA4H 2788/4885TLR8 4033/4885TLR7 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.